Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Ozempic for blood sugar control and Wegovy for weight loss both use different levels of semaglutide, a GLP-1 agonist. Victoza and Saxenda use another GLP-1 agonist, liraglutide.

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for a new and higher dose of its popular obesity medication, Wegovy ...